Promising colorectal cancer biomarkers for precision prevention and therapy

28Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) has been ranked as the third most prevalent cancer worldwide. Indeed, it represents 10.2% of all cancer cases. It is also the second most common cause of cancer mortality, and accounted for about 9.2% of all cancer deaths in 2018. Early detection together with a correct diagnosis and staging remains the most e_ective clinical strategy in terms of disease recovery. Thanks to advances in diagnostic techniques, and improvements of surgical adjuvant and palliative therapies, the mortality rate of CRC has decreased by more than 20% in the last decade. Cancer biomarkers for the early detection of CRC, its management, treatment and follow-up have contributed to the decrease in CRC mortality. Herein, we provide an overview of molecular biomarkers from tumor tissues and liquid biopsies that are approved for use in the CRC clinical setting for early detection, follow-up, and precision therapy, and of biomarkers that have not yet been o_cially validated and are, nowadays, under investigation.

Cite

CITATION STYLE

APA

Turano, M., Delrio, P., Rega, D., Cammarota, F., Polverino, A., Duraturo, F., … De Rosa, M. (2019, December 1). Promising colorectal cancer biomarkers for precision prevention and therapy. Cancers. MDPI AG. https://doi.org/10.3390/cancers11121932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free